Skip to main content
SpringerLink
Log in

Human Immunodeficiency Virus Type 1

  • Chapter
Book cover Molecular Pathology in Clinical Practice

  • 1928 Accesses

Abstract

Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), the causative agents of the acquired immunodeficiency syndrome (AIDS), are RNA viruses belonging to the genus Lentivirus of the family Retroviridae. Like all retroviruses, replication involves reverse transcription of the RNA genome into a double-stranded DNA molecule, with subsequent integration into the host genome. This integrated retroviral DNA is referred to as the provirus. Due to this complex replicative cycle, molecular assays used in the diagnosis and management of HIV-1 infection may target either HIV-1 RNA or proviral DNA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Connor R, Ho D, Kuritzkes DR, Richman D. Human Immunodeficiency Virus. In: Clinical Virology, 1st ed. Richman DD, Whitley RJ, and Hayden FG (eds.) Churchill Livingstone, New York; 1997:707–754.

    Google Scholar 

  2. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265.

    Article  PubMed  CAS  Google Scholar 

  3. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573–579.

    PubMed  CAS  Google Scholar 

  4. O’Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105–110.

    Article  PubMed  CAS  Google Scholar 

  5. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.

    Article  PubMed  CAS  Google Scholar 

  6. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Eng J Med. 1995;333:1662–1669.

    Article  CAS  Google Scholar 

  7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Eng J Med. 1997;337:725–739.

    Article  CAS  Google Scholar 

  8. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543–549.

    Article  PubMed  CAS  Google Scholar 

  9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD 4+ lymphocytes in HIV-1 infection. Nature. 1995;373:123–126.

    Article  PubMed  CAS  Google Scholar 

  10. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117–122.

    Article  PubMed  CAS  Google Scholar 

  11. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619–1624.

    Article  PubMed  CAS  Google Scholar 

  12. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med. 1996;2:625–629.

    Article  PubMed  CAS  Google Scholar 

  13. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Eng J Med. 1998;339:32–39.

    Article  Google Scholar 

  14. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001;134:25–29.

    PubMed  CAS  Google Scholar 

  15. Young NL, Shaffer N, Chaowanachan T, et al. Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J Acquir Immune Defic Syndr. 2000;24:401–407.

    PubMed  CAS  Google Scholar 

  16. Cunningham CK, Charbonneau TT, Song K, et al. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr Infect Dis J. 1999;18:30–35.

    Article  PubMed  CAS  Google Scholar 

  17. Steketee RW, Abrams EJ, Thea DM, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infect Dis. 1997;175:707–711.

    PubMed  CAS  Google Scholar 

  18. Centers for Disease Control. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:(RR-12):1–11.

    Google Scholar 

  19. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195–2199.

    Article  PubMed  CAS  Google Scholar 

  20. Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The VIRADAPT study: week 48 follow-up. Antivir Ther. 2000;5:65–70.

    PubMed  CAS  Google Scholar 

  21. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83–F93.

    Article  PubMed  CAS  Google Scholar 

  22. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice—the Havana trial. AIDS. 2002;16:209–218.

    Article  PubMed  Google Scholar 

  23. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440–450.

    PubMed  CAS  Google Scholar 

  24. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579–588.

    Article  PubMed  CAS  Google Scholar 

  25. Meynard J-L, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727–736.

    Article  PubMed  Google Scholar 

  26. Miller V. HIV drug resistance: overview of clinical data. J HIV Ther. 2001;6:68–72.

    PubMed  CAS  Google Scholar 

  27. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005;19:295–302.

    PubMed  Google Scholar 

  28. Hirsch MS, Conway B, D’Aquila RT, et al. Antiretroviral drug resistance testing in adults with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2003;37:113–128.

    Article  PubMed  Google Scholar 

  29. Erice A, Brambilla D, Bremer J, et al. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2000;38:2837–2845.

    PubMed  CAS  Google Scholar 

  30. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:2964–2969.

    PubMed  CAS  Google Scholar 

  31. Witt DJ, Kemper M, Stead A, Ginocchio C, Caliendo AM. Relationship of incremental specimen volumes and enhanced detection of human immunodeficiency virus type 1 RNA with nucleic acid amplification technology. J Clin Microbiol. 2000;38:85–89.

    PubMed  CAS  Google Scholar 

  32. Parekh B, Phillips S, Granade TC, Baggs J, Hu DJ, Respess R. Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses. 1999;15:133–142.

    Article  PubMed  CAS  Google Scholar 

  33. Jagodzinski LL, Wiggins DL, McManis JL, et al. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol. 2000;38:1247–1249.

    PubMed  CAS  Google Scholar 

  34. Pasquier C, Sandres K, Salama G, Puel J, Izopet J. Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA. J Virol Methods. 1999;81:123–129.

    Article  PubMed  CAS  Google Scholar 

  35. Nkengasong JN, Bile C, Kalou M, et al. Quantification of RNA in HIV Type 1 subtypes D and G by NucliSens and Amplicor Assays in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses. 1999;15:495–498.

    Article  PubMed  CAS  Google Scholar 

  36. Abravaya K, Esping C, Hoenle R, et al. Performance of a multiplex qualitative PCR LCx assay for detection of human immunodeficiency virus type 1 (HIV-1) group M subtypes, group O, and HIV-2. J Clin Microbiol. 2000;38:716–723.

    PubMed  CAS  Google Scholar 

  37. Nolte FS, Boysza J, Thurmond C, Clark WS, Lennox JL. Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:716–720.

    PubMed  CAS  Google Scholar 

  38. Segondy M, Izopet J, Pellegrin I, et al. Comparison of the Quantiplex HIV-1 RNA 2.0 assay with the Amplicor HIV-1 monitor 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. J Clin Microbiol. 1998;36:3392–3395.

    PubMed  CAS  Google Scholar 

  39. Dyer JR, Pilcher CD, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1999;37:447–449.

    PubMed  CAS  Google Scholar 

  40. Elbeik T, Charlebois E, Nassos P, et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5. J Clin Microbiol. 2000;38:1113–1120.

    PubMed  CAS  Google Scholar 

  41. Triques K, Coste J, Perret JL, et al. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol. 1999;37:110–116.

    PubMed  CAS  Google Scholar 

  42. Ginocchio CC, Wang XP, Kaplan MH, et al. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol. 1997;35:2886–2893.

    PubMed  CAS  Google Scholar 

  43. Sebire K, McGavin K, Land S, Middleton T, Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol. 1998;36:493–498.

    PubMed  CAS  Google Scholar 

  44. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol. 1998;36:1471–1479.

    PubMed  CAS  Google Scholar 

  45. Boom R, Sol C, Salimans M, Jansen C, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495–503.

    PubMed  CAS  Google Scholar 

  46. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J Clin Microbiol. 2000;38:323–326.

    PubMed  CAS  Google Scholar 

  47. Cassol S, Gill MJ, Pilon R, et al. Quantification of human immunodeficiency virus type 1 DNA from dried plasma spots collected on filter paper. J Clin Microbiol. 1997;35:2795–2801.

    PubMed  CAS  Google Scholar 

  48. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol. 1998;36:258–260.

    PubMed  CAS  Google Scholar 

  49. Bremer J, Nowicki M, Beckner S, et al. Comparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract. J Clin Microbiol. 2000;38:2665–2669.

    PubMed  CAS  Google Scholar 

  50. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2:753–759.

    Article  PubMed  CAS  Google Scholar 

  51. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998;14:869–876.

    Article  PubMed  CAS  Google Scholar 

  52. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 2000;38:2715–2721.

    PubMed  CAS  Google Scholar 

  53. Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-Genotype R method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol. 2000;38:3022–3028.

    PubMed  CAS  Google Scholar 

  54. Stuyver L, Wyseur A, Rombout A. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284–291.

    PubMed  CAS  Google Scholar 

  55. Servais J, Lambert C, Fontaine E, et al. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol. 2001;39:454–459.

    Article  PubMed  CAS  Google Scholar 

  56. Erali M, Page S, Reimer LG, Hillyard DR. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol. 2001;39:2157–2165.

    Article  PubMed  CAS  Google Scholar 

  57. Petropoulos CJ, Parkin NT, Limoli KL. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920–928.

    Article  PubMed  CAS  Google Scholar 

  58. Hertogs K, de Bethune MP, Miler V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269–276.

    Article  PubMed  CAS  Google Scholar 

  59. Mracna M, Becker-Pergola G, Dileanis J, et al. Performance of the Applied Biosystems ViroSeq HIV-1 genotyping system for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol. 2001;39:4323–4327.

    Article  PubMed  CAS  Google Scholar 

  60. Rozenbaum W, Charpentier C, Delphin N, et al. Comparative performance evaluation of a kit-based HIV-1 genotyping assay and a laboratory developed “home-brew” genotyping assay with samples of varying viral loads and non-B subtypes of group M virus [abstract 171]. Antiviral Therapy, 5th International Workshop on HIV Drug Resistance & Treatment Strategies. Scottsdale, AZ; 2001;6:130.

    Google Scholar 

  61. Brambilla D, Leung S, Lew J, et al. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol. 1998;36:311–314.

    PubMed  CAS  Google Scholar 

  62. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis. 1996;174:401–403.

    PubMed  CAS  Google Scholar 

  63. O’Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86:1082–1089.

    PubMed  CAS  Google Scholar 

  64. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727–1737.

    Article  PubMed  CAS  Google Scholar 

  65. Hirsch MS, Conway B, D’Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984–1991.

    Article  PubMed  CAS  Google Scholar 

  66. D’Aquila RT. Incorporating antiretroviral resistance testing into clinical practice. Medscape HIV/AIDS CME Circle. Web MD Medscape Health Network. 2002. Available at: http://www.medscape.com.

    Google Scholar 

  67. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr. 2002;31:128–136.

    PubMed  CAS  Google Scholar 

  68. Van Houtte M. Update on resistance testing. J HIV Ther. 2001;6:61–64.

    PubMed  Google Scholar 

  69. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13:F123–F127.

    Article  PubMed  CAS  Google Scholar 

  70. Keulen W, Brambilla D, Buimer M, et al. A study on HIV-1 genotyping proficiency in 125 laboratories, using the ENVA-3 panel [abstract 166]. Antiviral Therapy, 5th International Workshop on HIV Drug Resistance & Treatment Strategies. Scottsdale, AZ; 2001;6:127.

    Google Scholar 

  71. Wensing AM, Keulen W, Buimer M, Brambilla D, Schuurman R, Boucher C. Analysis of the world-wide evaluation study on HIV-1 genotype interpretation: ENVA-3 [abstract 133]. Antiviral Therapy, 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, AZ; 2001;6:101.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, 30322, USA

    Angela M. Caliendo MD, PhD (Vice Chair and Associate Professor)

Authors
  1. Angela M. Caliendo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, 10021, USA

    Debra G. B. Leonard MD, PhD (Professor and Vice Chair for Laboratory Medicine) (Professor and Vice Chair for Laboratory Medicine)

  2. Hematology, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Adam Bagg MD (Director) (Director)

  3. Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, 30322, USA

    Angela M. Caliendo MD, PhD (Vice Chair and Associate Professor) (Vice Chair and Associate Professor)

  4. Northwestern University Feinberg School of Medicine, Evanston, IL, 60201

    Karen L. Kaul MD, PhD (Professor) (Professor)

  5. Department of Pathology and Laboratory Medicine, Evanston Northwestern Healthcare, Evanston, IL, 60201, USA

    Karen L. Kaul MD, PhD (Professor) (Professor)

  6. Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, PA, 19104, USA

    Vivianna M. Van Deerlin MD, PhD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Caliendo, A.M. (2007). Human Immunodeficiency Virus Type 1. In: Leonard, D.G.B., Bagg, A., Caliendo, A.M., Kaul, K.L., Van Deerlin, V.M. (eds) Molecular Pathology in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-0-387-33227-7_36

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-33227-7_36

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33226-0

  • Online ISBN: 978-0-387-33227-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation